Characteristic | Octreotide N = 52 | Placebo N = 54 |
---|---|---|
Age in years, mean (SD) | 62.9 (13.6) | 66.3 (12.2) |
Gender, female, n (%) | 47 (90.4) | 38 (70.4) |
Performance status (AKPS), median (IQR) | 50 (40–60) | 50 (40–60) |
BPI pain score, median (IQR) | 3 (1–5) | 4 (1.25–5) |
Nauseaa, median (IQR) | 2 (1–2) | 1(1–2) |
Level of bowel obstruction | ||
 Gastric outlet/duodenal, n (%) | 5 (9.6) | 9 (16.7) |
 Small bowel/ multi-level, n (%) | 34 (65.4) | 34 (63.0) |
 Large bowel, n (%) | 2 (3.9) | 3 (5.6) |
 Indeterminate, n (%) | 11 (21.2) | 8 (14.8) |
EORTC QLQ-C15-Pal overall quality of life score, mean (SD) | 22.1 (24.3) | 31.5 (27.2) |